MedTrace Logo

The Use of AVL-3288 to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine

NCT03281694 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2024-11-06

No results posted yet for this study

Summary

Single-center, randomized, double-blind, placebo-controlled, proof-of-principle study to evaluate potential cognitive benefits of a single oral dose of AVL-3288 (3 mg) in the presence and absence of transdermal nicotine (7 mg/24 hrs) in healthy non-smokers, while monitoring the safety and tolerability of AVL-3288.

Conditions

  • Cognitive Change

Interventions

DRUG

Placebo

placebo skin patch and placebo oral solution

DRUG

Nicotine

nicotine skin patch (7 mg/24 hrs) and placebo oral solution

DRUG

AVL-3288

placebo skin patch and AVL-3288 oral solution (3 mg)

DRUG

Nicotine + AVL-3288

nicotine skin patch (7 mg/24 hrs) and AVL-3288 oral solution (3 mg)

Sponsors & Collaborators

  • University of Maryland, Baltimore

    lead OTHER

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-05-31
Primary Completion
2019-02-28
Completion
2019-02-28

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03281694 on ClinicalTrials.gov